COVID-19 Impact Analysis 

Pharmaceutical and biotech companies together with the governments are working to address the COVID-19 outbreak globally, from supporting the development of vaccines to planning for medicine supply chain challenges.

Currently, about 115 vaccine samples and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19.

Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future owing to the demand for vaccine and treatment drugs for COVID-19. This in turn is expected to have a significant impact on the global olanzapine market.

Top Impacting Factors

• The rise in the frequency of neurological disorders and the rising need for treatment of acute mania in bipolar disorders are the primary factors that drive the expansion of the olanzapine market.
• The rise in the number of people suffering from mental illness and emotional instability boosts the need for olanzapine as a first-line treatment for such conditions.
• As the world population grows at a rate of more than 1% per year, and individuals do not get enough neutrinos, diseases such as schizophrenia are spreading, further requiring pharmaceutical corporations to develop more medications to meet the rise in demand and benefit consumers.
• The prevalence of emotional sickness and mental disorders is increasing as a result of the change in lifestyles and the increase in tension in job and life, which is anticipated to create lucrative growth opportunities for the olanzapine market.
• However, medication side effects such as agitation and dysarthria and numerous regulatory requirements are expected to impede the expansion of the worldwide olanzapine market during the forecast period.

Market Trends

New Product Launches to Flourish Olanzapine Market

In June 2021, Alkermes announced that the U.S. Food and Drug Administration (USFDA) has approved LYBALVI (olanzapine and samidorphan) for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. LYBALVI is a once-daily, oral atypical antipsychotic composed of olanzapine, an established antipsychotic agent, and samidorphan, a new chemical entity.

In December 2020, Novartis teamed up with Cadent Therapeutics on treatment-resistant depression back when the neuro-focused biotech was working under the radar. Swiss Pharma is helping itself to the rest of Cadent’s pipeline in a deal worth $210 million upfront but that could net the latter up to $770 million in total. Under the deal, Novartis will buy out the milestones and royalties for the depression asset, MIJ821, which it is testing in a phase 2 study. It also picks up CAD-9303, a treatment for schizophrenia, and CAD-1883, which is in development for movement disorders.

Key Benefits of Report

• This study presents the analytical depiction of the olanzapine along with the current trends and future estimations to determine the imminent investment pockets.
• The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the olanzapine market share.
• The current market is quantitatively analyzed from 2020 to 2030 to highlight the olanzapine market growth scenario.
• Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market. 
• The report provides a detailed olanzapine market analysis based on competitive intensity and how the competition will take shape in coming years.

Questions Answered in Olanzapine Market Report

• Who are the leading market players active in the olanzapine market?
• What current trends will influence the olanzapine market in the next few years?
• What are the driving factors, restraints, and opportunities in the olanzapine market?
• What future projections would help in taking further strategic steps?
• What is olanzapine?
• What is the olanzapine market prediction for the future?
• Who are the leading global players in the olanzapine market?
• What are the current trends and predicted trends?
• What are the key benefits of the olanzapine market report?